Company
Company

Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

2seventybio

Main focus: Novel cellular therapies for the treatment of cancer

Company stage: Clinical

Diseases: Cancer (undisclosed which programmes use gene editing)

Genome editing tool: megaTAL-based genome editing

Funding stage: Public (NASDAQ:TSVT)

Location: Cambridge, MA, USA

Website: https://www.2seventybio.com/

Pipeline: https://www.2seventybio.com/our-science

Gene editing Partnerships: Novo Nordisk

2seventy bio was recently formed as a spin-out company from bluebird bio. The company focuses on next generation cell-based therapies for the treatment of cancer. The company holds a priprietary megaTAL technology, which it applies for genomic engineering of its therapies. Currently, however, it is undisclosed which of the company's early phase programmes are actually incorporating the megaTAL technology.

Tags

Hashtag2seventybio

Company: 2seventybio
close
Search CRISPR Medicine